Chimerix Inc. (NASDAQ:CMRX) and Gritstone Oncology Inc. (NASDAQ:GRTS) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chimerix Inc. 7.22M 14.46 69.47M -1.55 0.00 Gritstone Oncology Inc. N/A 3070.20 64.81M -2.28 0.00 We can see in table 1 the earnings per share, gross revenue and valuation of Chimerix Inc. and Gritstone Oncology Inc.
Table 2 represents Chimerix Inc. (NASDAQ:CMRX) and Gritstone Oncology Inc. (NASDAQ:GRTS)’s return on equity, return on assets and net margins. Net Margins Return on Equity Return on Assets Chimerix Inc. -962.19% -36.5% -34.7% Liquidity
The Current Ratio of Chimerix Inc. is 19.9 while its Quick Ratio stands at 19.9. The Current Ratio of rival Gritstone Oncology Inc. is 6.1 and its Quick Ratio is has 6.1. Chimerix Inc. is better equipped to clear short and long-term obligations than Gritstone Oncology Inc.
The Recommendations and Ratings for Chimerix Inc. and Gritstone Oncology Inc. are featured in the next table.
The average target price of Chimerix Inc. is $3.5, with potential upside of 70.73%. On the other hand, Gritstone Oncology Inc.’s potential upside is 82.27% and its average target price is $18.5. Based on the data delivered earlier, Gritstone Oncology Inc. is looking more favorable than Chimerix Inc., analysts opinion.
Insider & Institutional Ownership Chimerix Inc. and Gritstone Oncology Inc. has shares held by institutional investors as follows: 81% and 59.7%. Chimerix Inc.’s share held by insiders are 1.4%. Insiders Comparatively, held 2.3% of Gritstone Oncology Inc. shares. Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Chimerix Inc. 16.16% -1.29% -33.53% -45.11% -52.97% -10.51% Gritstone Oncology Inc. 6.08% 2.27% -46.26% 0% 0% -15.28% For the past year Chimerix Inc. has stronger performance than Gritstone Oncology Inc.
Gritstone Oncology Inc. beats Chimerix Inc. on 7 of the 11 factors.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
Click here to view original web page at Comparison of Chimerix Inc. (CMRX) and Gritstone Oncology Inc. (NASDAQ:GRTS)